QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 td-cowen-maintains-buy-on-charles-river-lowers-price-target-to-197

TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and lowers the price target from $205 to $197.

 jp-morgan-maintains-neutral-on-charles-river-raises-price-target-to-165

JP Morgan analyst Casey Woodring maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $160 to ...

 barclays-maintains-overweight-on-charles-river-raises-price-target-to-210

Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $195 to ...

 baird-upgrades-charles-river-to-outperform-raises-price-target-to-199

Baird analyst Eric Coldwell upgrades Charles River (NYSE:CRL) from Neutral to Outperform and raises the price target from $1...

 charles-river-beat-expectations-but-why-is-the-stock-falling

Charles River stock dips as Q3 revenue slips, EPS beats estimates, and company raises 2025 outlook with cost cuts and $1 billio...

 charles-river-raises-fy2025-adj-eps-guidance-from-990-1030-to-1010-1030-vs-1019-est-lowers-fy2025-sales-guidance-from-3949b-4030b-to-3848b-3989b-vs-3991b-est

The Company's 2025 guidance for revenue and earnings per share is as follows:2025 GUIDANCECURRENTPRIORRevenue growth/(decre...

 charles-river-lowers-fy2025-gaap-eps-guidance-from-425-465-to-415-435-vs-457-est

The Company's 2025 guidance for revenue and earnings per share is as follows:2025 GUIDANCECURRENTPRIORRevenue growth/(decre...

 charles-river-laboratories-and-the-francis-crick-institute-enters-collaboration-to-advance-antibody-drug-conjugate-drug-discovery-and-development

Charles River Laboratories International, Inc. (NYSE:CRL) and The Francis Crick Institute (Crick) today announced a new collabo...

 charles-river-announces-strategic-collaboration-with-x-chem-to-enhance-hit-identification-capabilities-and-accelerate-discovery-of-novel-therapeutics

X-Chem's DNA-encoded library complements Charles River's discovery expertise to accelerate hit identificationCharles Ri...

 mizuho-maintains-neutral-on-charles-river-raises-price-target-to-174

Mizuho analyst Ann Hynes maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $155 to $174.

 earlier-today-charles-river-and-toxys-collaborate-to-offer-reprotracker-assay-for-rapid-developmental-toxicity-testing

Charles River Laboratories International, Inc. (NYSE:CRL) and Toxys today announced a collaboration that offers Charles River&#...

 why-charles-river-stock-may-struggle-in-its-final-phase

Adhishthana.com notes Charles River Stock is nearing its Phase 18, with momentum weakening and long-term outperformance looking...

 william-blair-upgrades-charles-river-to-outperform

William Blair analyst Matt Larew upgrades Charles River (NYSE:CRL) from Market Perform to Outperform.

 evercore-isi-group-maintains-outperform-on-charles-river-raises-price-target-to-200

Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION